1. Introduction {#sec1}
===============

Fracture is a common and frequent disease that occurs in patients with various injuries or osteoporosis \[[@B1]\]. In China, the population-weighted incidence of traumatic fractures of the legs, arms, or trunk in 2014 was 3.21 per 1,000 people (95% CI 2.83--3.59) \[[@B2]\]. Osteoporotic fractures are estimated to account for half of all fractures by 2050, and the estimated cost of osteoporotic hip fractures worldwide may reach \$131 billion \[[@B3]\]. Therefore, the study of drugs for the prevention and treatment of fractures plays an important role in promoting patient health and reducing family economic pressure.

Recently, DR, one of the plants from Davalliaceae and Davallia Sm., has been widely used in the prevention and treatment of various fractures due to excellent treatment, low side effects, extensive use, and safety \[[@B4]\]. Animal experiments have confirmed that DR could alter the bone histomorphology and increase the number of trabeculae by 10% \[[@B5]\], and its osteogenesis is related to Runx2 and BMP-2 signaling pathways \[[@B6]\]. In addition, it is believed that the various ingredients contained in an herb could regulate multiple targets in different signaling pathways and produce synergistic therapeutic effects \[[@B7]\]. However, such research has not been carried out in the treatment of fractures with DR.

Network pharmacology based on systems biology and polypharmacology has achieved a paradigm shift from "one drug, one goal" to "multi-ingredient therapy, biological network," which has attracted the attention of Chinese medicine researchers and has been recognized as an effective tool for elucidating multiple components, targets, synergistic effects, and mechanisms of Chinese medicine \[[@B8]--[@B10]\]. It is reported that network pharmacology predicts the clinical efficacy, pathways, and side effects of drugs by constructing drug-drug networks, disease-drug networks, and disease-disease networks, providing valuable information for improving the clinical efficacy, reducing toxicity, and elucidating multimechanisms of drugs \[[@B11]\]. For example, Wang Nani found that Er-Xian Decotion has 13 main components closely related to 65 osteoporosis-related targets by using network pharmacology, thereby constructing Er-Xian Decotion component-osteoporosis target network and potential antiosteoporosis mechanism \[[@B12]\]. Yueying et al. identified 108 compounds, 86 potential targets, and 47 signal transduction pathways that Danshiliuhao Granule regulates liver fibrosis by the network pharmacology method, which reflects the multicomponent, multitarget, and multichannel characteristics of Chinese herbal medicine in antiliver fibrosis \[[@B13]\]. Therefore, in order to reveal the relationship between fracture and the active ingredients involved in the DR, we conducted network pharmacology to achieve this goal from protein and gene level. We collected the information of targets from active ingredients in DR and targets of fracture from several databases, respectively, and used network pharmacology to explore the potential synergistic mechanisms of DR for treating fracture.

2. Materials and Methods {#sec2}
========================

2.1. Screening of Active Ingredients of *Drynariae Rhizoma* {#sec2.1}
-----------------------------------------------------------

Traditional Chinese Medicine Systems Pharmacology (TCMSP, <http://lsp.nwu.edu.cn/>, Version 2.3) Database and Analysis Platform includes chemicals, targets, and drug-target-disease networks, as well as pharmacokinetic properties involving oral bioavailability, druglikeness, blood-brain-barrier, and so on \[[@B14]\]. There were 71 compounds of DR which were obtained from the TCMSP. The potential active ingredients of DR for treating fracture were screened according to their oral bioavailability (OB) ≥30% and druglikeness (DL) ≥0.18 recommended by TCMSP.

2.2. Obtaining the Chemical Structure of Active Ingredients {#sec2.2}
-----------------------------------------------------------

The structure of the potential active ingredients of DR was downloaded from TCMSP and stored in mol2 format. If there was no chemical structure, the PubChem compound was put into the PubChem (<https://pubchem.ncbi.nlm.nih.gov/>) to download a chemical structure and save it in sdf format, or the PubChem compound was put into the Zinc database (<https://zinc.docking.org/>) to download a chemical structure and save it in mol2 format. The related SMILES of potential active ingredients was received from TCMSP or PubChem or Zinc database. Then, the SMILES was put into the Swiss Target Prediction database (<http://www.swisstargetprediction.ch/>) to obtain the related drug target and save it.

2.3. Gene Targets of *Drynariae Rhizoma* {#sec2.3}
----------------------------------------

The DRAR-CPI server (<http://cpi.bio-x.cn/drar>, update in 2017-7-26) has a collection of drug molecules and targetable human proteins \[[@B15]\]. When submitting a drug molecule, the server docks the drug uploaded by users with the three-dimensional structure of all protein targets in the database, scores, and ranks them with the affinity scoring function based on the protein-ligand interaction, thereby predicting the potential protein targets of human-targetable drugs \[[@B15], [@B16]\]. This affinity score is called *Z*-score in the DRAR-CPI server \[[@B17]\]. Protein-ligand interaction with *Z*-score \<−0.5 was recommended by DRAR-CPI as a potential protein target for human-targetable drugs \[[@B16]\]. We uploaded the potential active ingredients of DR in mol2 or sdf format and used *Z*-score \<−0.5 to select potential protein targets for DR. A total of 1760 proteins with *Z*-score \<−0.5 and 355 protein targets were obtained after deletion of the duplicate data. The PDB ID of the protein targets were inputted into UniProt KB (<http://www.uniprot.org/uniprot/>) of the UniProt database, and the "popular organisms" was selected as human to obtain the gene targets associated with the potential active ingredient of DR.

2.4. Gene Target Prediction for *Drynariae Rhizoma* to Treat Fractures {#sec2.4}
----------------------------------------------------------------------

The following electronic databases were searched to identify the genes related to fractures: Genetic Association Database (<https://geneticassociationdb.nih.gov/>), Therapeutic Targets Database (<http://bidd.nus.edu.sg/BIDD-Databases/TTD/TTD.asp>), PharmGkb database (<https://www.pharmgkb.org/>), GeneCards database (<http://www.genecards.org/>), and OMIM database (<http://www.ncbi.nlm.nih.gov/omim>). Then, the duplicate data and false-positive genes were deleted. Finally, the Venny tool (<http://bioinfogp.cnb.csic.es/tools/venny/index.html>, Version 2.1) was used to identify the common gene targets of DR and fracture, which may be the potential targets for DR to treat fractures.

2.5. Constructing the Ingredient-Target Network of *Drynariae Rhizoma* {#sec2.5}
----------------------------------------------------------------------

The common gene targets of DR and fracture were introduced into the Cytoscape software (Version 3.4.0) to construct an ingredient-target network of *Drynariae Rhizoma* and analyze the topology properties of the network, including degree, betweenness centrality, and closeness centrality \[[@B18]\]. The degree describes the number of connections to a node in the network, indicating interaction with other nodes in the network. Betweenness centrality measures the proportion of a node between shortest paths among other nodes, suggesting the importance of nodes in maintaining network tightness. Closeness centrality indicates the degree of nodes close to the "center" of the network. A node with high degree, betweenness centrality, and closeness centrality values means that it plays a very important role in the network \[[@B18]\].

2.6. Constructing Protein-Protein Interaction (PPI) of *Drynariae Rhizoma* {#sec2.6}
--------------------------------------------------------------------------

The String database (<https://string-db.org/>, Version 10.5) is a database containing known and predicted PPIs, which collect and integrate a large number of protein interactions involving 9,643,763 proteins and 1,380,838,440 interactions, including experimental data and interactive prediction data derived from bioinformatic methods \[[@B19]\]. Common gene targets of DR and fracture were imported into the STRING database, and the species were set to humans for PPIs. Then, the highest confidence was set to 0.9 in the minimum required interaction score and the results were updated. The TSV format of the updated results were downloaded. Then, node1, node2, and combined scores were extracted and imported into the Cytoscape software to create a PPI network, and the network was analyzed as follows: Step 1: analyze the topology properties of the network: cytoscape ⟶ tools ⟶ network analyzer ⟶ network analysis ⟶ analyze network, save the CSV format of the network result and extract the degree value. Step 2: create a network map according to the degree: cytoscape ⟶ tool ⟶ network analyzer ⟶ network analysis ⟶ generate style from statistics ⟶ map node size to degree ⟶ map node color to degree  and save the PPI network map.

2.7. Molecular Docking {#sec2.7}
----------------------

SystemsDock (<http://systemsdock.unit.oist.jp>, Version 2.0) is a web server for network pharmacology-based prediction and analysis that could be used to illustrate the role of ligands on a complex molecular network \[[@B20]\]. It evaluates the protein-ligand binding potential of molecular docking by combining docking with the intelligence (dock-IN) score. The dock-IN score is the negative logarithm of the experimental dissociation/inhibition constant (pKd/pKi), which ranges from 0 to 10, indicating weak to strong binding \[[@B20]\]. It is believed that the docK-IN score above 4.25 indicates a slight binding potential between the protein and ligand; a value greater than 5.0 indicates a moderate binding potential, and a value greater than 7.0 indicates a strong binding potential \[[@B16]\]. We extracted the top 5 proteins with the highest degree value in the PPI network. The proteins that were recognized by systemsDock docked with the potential active ingredients of DR to receive the dock-IN score. The results were saved, and their dock-IN score was analyzed to assess the binding potentials between the potential active ingredients of DR and protein targets.

2.8. GO Functional Analysis and KEGG Pathway Enrichment Analysis {#sec2.8}
----------------------------------------------------------------

GO (<http://www.geneontology.org>) is widely used for annotation of gene function, providing detailed annotations of gene function in terms of biological process (BP), cellular component (CC), and molecular function (MF), respectively \[[@B21]\]. Database for annotation, visualization, and integrated discovery (David, <https://david.ncifcrf.gov/>, Version 6.8) is a functional genomic annotation database that provides bioinformatics annotation for genes or proteins based on the gene annotation function of the GO database and the signaling pathway information of the KEGG database \[[@B22]\]. We performed GO functional analysis and KEGG pathway enrichment analysis in the David database. The procedure was as follows: Step 1: paste the common gene targets of DR and fracture list. Step 2: select "OFFICIAL_GENE_SYMBOL" in "Select Identifier." Step 3: select "Gene List" in "List Type." Step 4: select "*Homo sapiens*" in species. Step 5: submit list. Step 6: download the results of BP, CC, and MF in the gene ontology. Step 7: download the results of KEGG pathway in the pathways. Step 8: targets with *P* \< 0.05 were screened and sorted by count (number of targets), and the top-ranked biological processes or KEGG pathways were extracted. Step 9: BP, CC, and MF were designed using GraphPad Prism 5.0 software. The KEGG pathways were designed by the advanced bubble chart of the omicshare tool (<http://omicshare.com/tools/Home/Soft/getsoft/type/index>).

2.9. Collect Protein Class Corresponding to Common Gene Targets {#sec2.9}
---------------------------------------------------------------

DisGeNET (<http://www.disgenet.org/web/DisGeNET/menu>, Version 5.0) is a discovery platform that contains one of the largest publicly available genes and variants associated with human disease. It could be used to analyze the properties of disease genes and investigate the molecular basis of specific diseases and their comorbidities, as well as adverse drug reactions \[[@B23]\]. We used the search function of the DisGeNET platform to retrieve the protein class corresponding to common gene targets.

2.10. Pathway Integration {#sec2.10}
-------------------------

We used the KEGG Mapper tool in the KEGG database (<http://www.kegg.jp/>) to retrieve some pathways of DR for fractures and then integrate into a final pathway map. The procedure was as follows: Step 1: used the UniProt KB search function of the UniProt database to retrieve the UniprotID of the common gene targets. Step 2: import the UniProt ID of the common gene targets. Step 3: set the parameters: search against: hsa, primary ID: NCBI-UniProt ID, and examples: *Homo sapiens* pathway. Step 4: download the PI3K-AKT, MAPK, Ras, and VEGF signaling pathways. Step 5: integrate the signal path.

3. Results {#sec3}
==========

3.1. Active Ingredients of *Drynariae Rhizoma* {#sec3.1}
----------------------------------------------

A total of 71 ingredients of DR were retrieved from TCMSP, and 18 active ingredients were screened according to the biological functions of DR. However, marioside_qt (Molecule ID: MOL009087) was removed because it could not be recognized by the PubChem or Zinc database. The remaining 17 active ingredients are shown in [Table 1](#tab1){ref-type="table"}, including (2R)-5,7-dihydroxy-2-(4-hydroxyphenyl)chroman-4-one, aureusidin, eriodictyol (flavanone), stigmasterol, beta-sitosterol, kaempferol, naringenin, (+)-catechin, eriodictyol, digallate, luteolin, 22-stigmasten-3-one, cyclolaudenol acetate, cycloartenone, cyclolaudenol, davallioside A_qt, and xanthogalenol.

3.2. Gene Target Prediction {#sec3.2}
---------------------------

A total of 303 gene targets associated with the potential active ingredients of DR were retrieved in the UniProt database. A total of 3,173 fracture-related genes were received, and 3,054 genes remained after deletion of the duplicate and false-positive genes. Common gene target screening for fracture and DR are shown in [Figure 1](#fig1){ref-type="fig"}. A total of 144 common gene targets of DR and fracture were received, indicating the potential targets for DR to treat fractures, as shown in [Table 2](#tab2){ref-type="table"}.

3.3. Ingredient-Target Network of *Drynariae Rhizoma* {#sec3.3}
-----------------------------------------------------

The active ingredients and gene targets of DR was inputted into Cytoscape software to construct the ingredient-target network, as shown in [Figure 2](#fig2){ref-type="fig"}. In the network, the pink oval nodes represent the main active ingredients of DR, and the light green rectangle nodes represent the potential gene targets for DR to treat fractures. The line represents the correlation between the active ingredients of DR and the gene targets. There are 161 nodes and 774 lines in the network. An active ingredient could be linked to different gene targets, and a gene target could be linked to different active ingredients, suggesting the multicomponent and multitarget characteristics of DR. The topology properties of active ingredients of DR are shown in Supplementary [Table 1](#tab1){ref-type="table"}. Both cyclolaudenol and cycloartenone were linked to a maximum number of gene targets, with 70 (48.61%) different gene targets. Cyclolaudenol acetate was linked to 54 (37.5%) different gene targets. Xanthogalenol was linked to a minimum number of gene targets for a total of 29 (20.14%). In addition, there were four gene targets with the top four degree values, betweenness centrality, and closeness centrality at the same time ([Table 3](#tab3){ref-type="table"}), which were NCOA1, GSK3B, TTPA, and MAPK1.

3.4. Protein-Protein Interaction of *Drynariae Rhizoma* {#sec3.4}
-------------------------------------------------------

The PPI network of DR is shown in [Figure 3](#fig3){ref-type="fig"}. In the network, the node represents the protein, and the size and color of the node represent the value of the degree. The larger the node and the brighter the color (yellow to blue), the greater the value of the degree. The line indicates the association between proteins. Results showed that there were 143 nodes and 315 lines.

Degree in the network indicates the number of proteins that a protein has interacting with. In other words, top-degree protein targets screened in PPI plays a pivotal role in the treatment of fractures with DR. Five important protein targets with top degree of DR were identified in the PPI network and are shown in [Table 4](#tab4){ref-type="table"}. They were MAPK1, SRC, HRAS, RXRA, and NCOA1.

3.5. Molecular Docking {#sec3.5}
----------------------

Three important protein targets with top degree of DR were identified by SystemsDock, including SRC, RXRA, and NCOA1. Dock-IN score of these three proteins docked with 17 active ingredients of DR are shown in [Table 5](#tab5){ref-type="table"}. Molecular docking results showed that there were 17 (33.33%) with a dock-IN score greater than 7.0, 24 (47.06%) with a dock-IN score between 7.0 and 5.0, 8 (15.69%) with a dock-IN score between 5.0 and 4.25, and 2 (3.92%) with a dock-IN score less than 4.25.

3.6. Gene Ontology (GO) Functional Analysis and KEGG Pathway Enrichment Analysis {#sec3.6}
--------------------------------------------------------------------------------

Enriched gene ontology terms for BP, CC, and MF of potential therapeutic fracture targets from the main active ingredients of DR are shown in [Figure 4](#fig4){ref-type="fig"}. In the BP ([Figure 4(a)](#fig4){ref-type="fig"}), positive regulation of transcription from RNA polymerase II promoter involved 33 (22.92%) potential therapeutic fracture targets, signal transduction involved 30 (20.84%) potential therapeutic fracture targets, negative regulation of transcription from RNA polymerase II promoter involved 20 (13.89%) potential therapeutic fracture targets, positive regulation of transcription and DNA-template involved 19 (13.19%) potential therapeutic fracture targets, and transcription initiation from RNA polymerase II promoter involved 18 (12.5%) potential therapeutic fracture targets. In the CC ([Figure 4(b)](#fig4){ref-type="fig"}), cytosol involved 63 (43.75%) potential therapeutic fracture targets, extracellular exosome involved 60 (41.67%) potential therapeutic fracture targets, cytoplasm involved 58 (40.28%) potential therapeutic fracture targets, nucleus involved 56 (38.89%) potential therapeutic fracture targets, and plasma membrane involved 53 (36.81%) potential therapeutic fracture targets. In the MF ([Figure 4(c)](#fig4){ref-type="fig"}), protein binding involved 110 (76.39%) potential therapeutic fracture targets, zinc ion binding involved 31 (21.53%) potential therapeutic fracture targets, identical protein binding involved 29 (20.14%) potential therapeutic fracture targets, ATP binding involved 27 (18.75%) potential therapeutic fracture targets, and enzyme binding involved 23 (15.97%) potential therapeutic fracture targets.

Enriched KEGG pathways of potential targets for treating fracture from the main active ingredients of DR are shown in [Figure 5](#fig5){ref-type="fig"}. The MAPK signaling pathway was identified as an important signaling pathway involving 17 (11.81%) potential therapeutic fracture targets with *P*=7.82 × 10^−6^. The PI3K-Akt signaling pathway involved 17 (11.81%) potential therapeutic fracture targets, the Rap1 signaling pathway involved 14 (9.72%) potential therapeutic fracture targets, the Ras signaling pathway involved 14 (9.72%) potential therapeutic fracture targets, and the signaling pathways regulating pluripotency of stem cells involved 12 (9.03%) potential therapeutic fracture targets.

3.7. Protein Class Corresponding to Common Gene Targets {#sec3.7}
-------------------------------------------------------

The protein class corresponding to potential targets for treating fracture from the main active ingredients of DR is presented in [Table 6](#tab6){ref-type="table"}. The results showed that DR treatment of the fracture process involved a variety of substances, such as signaling molecule, transcription factor, receptor, enzyme modulator, chaperone, cell adhesion molecule, protein (transporter, transfer protein, carrier protein, calcium-binding protein, defense protein, and immune protein), enzyme modulator, and enzymes (oxidoreductase, kinase, phosphatase, hydrolase, ligase, protease, isomerase, lyase, enzyme regulator, and transferase).

3.8. Signaling Pathway Integration {#sec3.8}
----------------------------------

Four pathways associated with the potential targets of DR main active ingredients for treating fracture are presented in [Figure 6](#fig6){ref-type="fig"}. The arrow (⟶) indicates the promoting effect, the T-arrows (⊣) indicate the inhibition, and the arrows of different colors represent different signaling pathways. The targets of the signaling pathway were marked as light blue, and the potential targets of DR main active ingredients for treating fracture were marked as dark blue. There were 21 (14.58%) potential targets of main active ingredients of DR for treating fracture in the PI3K-AKT, MAPK, Ras, and VEGF signaling pathways, indicating that the fracture targets play a role in these signaling pathways. In addition, some targets play a role in a variety of signaling pathways, such as Ras, RafB, AKT/PKB, PI3K, ERK, and JNK.

4. Discussion {#sec4}
=============

In order to reveal the relationship between fracture and the active ingredients involved in the DR, we predicted the mechanism of DR treatment fractures by constructing a biological network of interactions between active ingredients and common gene targets and common protein targets from a molecular level. A total of 17 active ingredients of DR were received in our study, including (2R)-5,7-dihydroxy-2-(4-hydroxyphenyl)chroman-4-one, aureusidin, eriodictyol (flavanone), stigmasterol, beta-sitosterol, kaempferol, naringenin, (+)-catechin, eriodictyol, digallate, luteolin, 22-stigmasten-3-one, cyclolaudenol acetate, cycloartenone, cyclolaudenol, davallioside A_qt, and xanthogalenol. Most of them were polyphenolic compounds, which are also called flavonoids. Flavonoids are considered to be the main active ingredients of DR and have been reported to reduce bone loss in ovariectomized rats \[[@B24]\]. In addition, Kang Suk-Nam finds that the total phenolics and flavonoids of DR are better extracted with 70% ethanol instead of water, and this ethanol extraction method also makes these extracts have higher antioxidant activity and in vitro antiosteoporosis effect \[[@B25]\]. In the ingredient-target network, all active ingredients were also identified to bind well to the fracture gene targets, binding to at least 29 (20.14%) different gene targets. Therefore, the 17 active ingredients of DR may have the effect of reducing bone loss and promoting fracture healing.

In our study, 144 common gene targets of DR and fracture were received, and 774 interactions between the active ingredients of DR and common gene targets were found. Some gene targets have been confirmed by clinical trials or animal experiments. For example, Guimarães et al. found that polymorphisms in the FGFR1 and BMP4 genes were associated with fracture nonunion in patients \[[@B26]\]. And our team\'s previous study also found that the total flavonoids of DP could promote osteogenesis and mineralization in rats with tibial defects by increasing the gene expression of BMP2, BMP4, BMPR1A, and Smadl \[[@B27]\]. In the ingredient-target network, NCOA1, GSK3B, TTPA, and MAPK1 were identified as important gene targets based on degree values, betweenness centrality, and closeness centrality. Qin et al. found that NCOA1 promotes angiogenesis by upregulating HIF1*α*- and AP-1-mediated VEGFa transcription \[[@B28]\]. Galli et al. demonstrated by cell experiments that inhibition of GSK3B could increase cytoplasmic availability of b-catenin, thereby enhancing Wnt classical signaling and osteoblastic differentiation \[[@B29]\]. Fujita et al. found that mice deficient in TTPA developed a high bone mass phenotype in vertebrae and long bones due to lower bone resorption \[[@B30]\]. Matsushita et al. confirmed that MAPK1 (also called ERK2) plays an important role in osteoblast differentiation and osteoclastogenesis \[[@B31]\]. These gene targets are involved in vascularization, osteoblast differentiation, and osteoclastogenesis in fracture repair. Besides, we found that one active ingredient can interact with different gene targets, and one gene target can interact with different active ingredients, which is consistent with the modern drug theory of "multi-ingredient, multitarget" \[[@B9]\].

To identify the interactions of proteins corresponding to common genes, we conducted a PPI network. A total of 143 common protein targets for DR and fracture were received, with 315 PPIs. In addition, MAPK1, SRC, HRAS, RXRA, and NCOA1 were identified as the five most important target proteins. Previous studies have found that MAPK1 and SRC could promote proliferation and differentiation of myeloid cells and inhibit apoptosis \[[@B32], [@B33]\]. Clinical cases have found that elevated levels of fibroblast growth factor 23 in patients with dysplasia are associated with HRAS mutations \[[@B34]\]. RXRA is an essential cofactor in the action of 1,25-dihydroxyvitamin D, and umbilical cord RXRA methylation was inversely related to offspring bone mineral content \[[@B35]\]. Coronnello et al. found that NCOA1 modulate the estrogen effects in bone, and miR-488-5p overexpression reduces NCOA1 protein levels, thereby reducing bone mineral density \[[@B36]\]. These protein targets are associated with bone growth and angiogenesis in fracture repair. At the same time, we docked SRC, RXRA, and NCOA1 with 17 potential active ingredients of DR and found that 41 (80.39%) had moderate binding potential, suggesting that DR could bind well to fracture-related protein targets.

In order to identify the function of the common gene, we performed GO functional analysis on these genes. The results showed that the common gene involves multiple processes, parts and functions in BP, CC, and MF, which was consistent with existing studies about DR and fracture repair. For example, in the BP, 33 (22.92%) gene targets were involved in positive regulation of transcription from the RNA polymerase II promoter, and 30 (20.84%) gene targets were involved in signal transduction. Previous studies have shown that the promoter activates the polymerase to bind precisely to the template DNA and has the specificity of transcription initiation \[[@B37]\]. The RNA polymerase II promoter responsible for mRNA transcription is the largest and most important class of promoters \[[@B37]\]. This provides conditions for DR to initiate osteogenic targets. Besides, some signal transduction genes have been found in experiments. Song Nan found that VEGFR-2 may play a signal transduction role for naringin, one ingredient of DR, to stimulate angiogenesis and promote fracture healing \[[@B38]\]. In the CC, 63 (43.75%) gene targets were involved in cytosol, 60 (41.67%) gene targets were involved in extracellular exosome, and 58 (40.28%) gene targets were involved in cytoplasm. This indicates that the recovery of the fracture requires the support of various components in the cell, which is consistent with previous studies \[[@B39]\]. In the MF, 110 (76.39%) gene targets were involved in protein binding, suggesting that mutual recognition between proteins has good gene regulation conditions. This is consistent with the protein class corresponding to the potential target. These results were further validated in the protein class corresponding to the common gene. In the protein class, all of these common genes have been found to regulate a variety of fracture-related molecules, such as transcription factors, receptors, enzyme regulators, molecular chaperones, cell adhesion molecules, enzyme, and so on.

In order to identify the synergistic mechanism of DR for fracture, we performed KEGG pathway enrichment analysis and summarized some important signaling pathways, which provides direction for future research. In the KEGG pathway enrichment analysis, 17 (11.81%) gene targets were involved in MAPK signaling pathway, 17 (11.81%) gene targets were involved in PI3K-Akt signaling pathway, 14 (9.72%) gene targets were involved in Ras signaling pathway, and 6 (4.17%) gene targets were involved in VEGF signaling pathway, which suggest that common gene targets play a role in repairing fractures in multiple signaling pathways. MAPK and PI3K/AKT signaling pathways have been demonstrated to promote osteoblastic bone formation \[[@B40]\]. Zhang et al. confirmed that total flavonoids from DR promote the osteogentic differentiation of ciliary neurotrophic factor-modified myoblasts by activating p38 MAPK signaling pathway \[[@B41]\]. Moreover, total flavonoids of DR could promote osteogenic differentiation of rat dental pulp stem cells via the PI3K/Akt pathway \[[@B42]\]. Lin et al. found that the effect of naringin on the healing of fracture may be related to the promotion of the synthesis and secretion of cellular chemokines (CXCL5, CXCL6) and enhancement of mesenchymal stromal cell migration through Ras signaling pathway \[[@B43]\]. In addition, naringin stimulates angiogenesis by regulating the VEGF/VEGFR-2 signaling pathway in rats, thereby promoting fracture healing \[[@B38]\]. However, the mechanism of some active ingredients of DR in the treatment of fractures has not yet been verified. Therefore, we integrated MAPK, PI3K/AKT, Ras, and VEGF signaling pathways to provide a reference for researchers to verify the mechanism of other DR active ingredients in the treatment of fractures.

5. Conclusion {#sec5}
=============

We collected the gene and protein targets of fractures and active ingredients of DR and then used network pharmacology to reveal the correlation between drugs and diseases and the potential synergistic mechanism of different targets of DR in the treatment of fractures, which provides a reference for the development of new drugs.
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![Venn diagram of common gene target screening for fracture and *Drynariae Rhizoma*.](ECAM2019-7342635.001){#fig1}

![Ingredient-target network of *Drynariae Rhizoma*. *Note*. The pink oval nodes (![](ECAM2019-7342635.i001.jpg)) are the main active ingredients of *Drynariae Rhizoma*, and the light green rectangle (![](ECAM2019-7342635.i002.jpg)) is the potential target for treating fracture of *Drynariae Rhizoma*.](ECAM2019-7342635.002){#fig2}

![Protein-protein interaction network of *Drynariae Rhizoma*. *Note*. The size and the color of the node represents the value of the degree (yellow ⟶ orange ⟶ blue indicates that the degree value is from low to high, and the small circle represents a low degree value).](ECAM2019-7342635.003){#fig3}

![Enriched gene ontology terms of potential therapeutic fracture targets from main active ingredients of *Drynariae Rhizoma*. *Note*. (a) Biological process (BP), (b) cellular component (CC), and (c) molecular function (MF).](ECAM2019-7342635.004){#fig4}

![Enriched KEGG pathways of potential targets for treating fracture from main active ingredients of *Drynariae Rhizoma*.](ECAM2019-7342635.005){#fig5}

![Antifracture pathways of potential targets for treating fracture from main active ingredients of *Drynariae Rhizoma*. *Note*. The arrow (⟶) indicates the promoting effect, the T-arrows (⊣) indicate the inhibition, and the arrows of different colors represent different signaling pathways. The targets of the signaling pathway were marked as light blue, and the potential targets of main active ingredients of DR for treating fracture were marked as dark blue.](ECAM2019-7342635.006){#fig6}

###### 

Main active ingredients in *Drynariae Rhizoma*.

  No.   Molecule ID   Molecule name                                         Chemical formula   Structure                             OB (%)   DL
  ----- ------------- ----------------------------------------------------- ------------------ ------------------------------------- -------- ------
  1     MOL001040     (2R)-5,7-Dihydroxy-2-(4-hydroxyphenyl)chroman-4-one   C~15~H~12~O~5~     ![](ECAM2019-7342635.tab1.i001.jpg)   42.36    0.21
  2     MOL001978     Aureusidin                                            C~15~H~10~O~6~     ![](ECAM2019-7342635.tab1.i002.jpg)   53.42    0.24
  3     MOL002914     Eriodictyol (flavanone)                               C~15~H~12~O~6~     ![](ECAM2019-7342635.tab1.i003.jpg)   41.35    0.24
  4     MOL000449     Stigmasterol                                          C~29~H~48~O        ![](ECAM2019-7342635.tab1.i004.jpg)   43.83    0.76
  5     MOL000358     *β*-Sitosterol                                        C~29~H~50~O        ![](ECAM2019-7342635.tab1.i005.jpg)   36.91    0.75
  6     MOL000422     Kaempferol                                            C~15~H~10~O~6~     ![](ECAM2019-7342635.tab1.i006.jpg)   41.88    0.24
  7     MOL004328     Naringenin                                            C~15~H~12~O~5~     ![](ECAM2019-7342635.tab1.i007.jpg)   59.29    0.21
  8     MOL000492     (+)-Catechin                                          C~15~H~14~O~6~     ![](ECAM2019-7342635.tab1.i008.jpg)   54.83    0.24
  9     MOL005190     Eriodictyol                                           C~15~H~12~O~6~     ![](ECAM2019-7342635.tab1.i009.jpg)   71.79    0.24
  10    MOL000569     Digallate                                             C~14~H~10~O~9~     ![](ECAM2019-7342635.tab1.i010.jpg)   61.85    0.26
  11    MOL000006     Luteolin                                              C~15~H~10~O~6~     ![](ECAM2019-7342635.tab1.i011.jpg)   36.16    0.25
  12    MOL009061     22-Stigmasten-3-one                                   C~29~H~48~O        ![](ECAM2019-7342635.tab1.i012.jpg)   39.25    0.76
  13    MOL009063     Cyclolaudenol acetate                                 C~33~H~54~O~2~     ![](ECAM2019-7342635.tab1.i013.jpg)   41.66    0.79
  14    MOL009075     Cycloartenone                                         C~30~H~48~O        ![](ECAM2019-7342635.tab1.i014.jpg)   40.57    0.79
  15    MOL009076     Cyclolaudenol                                         C~31~H~52~O        ![](ECAM2019-7342635.tab1.i015.jpg)   39.05    0.79
  16    MOL009078     Davallioside A_qt                                     C~25~H~29~NO~12~   ![](ECAM2019-7342635.tab1.i016.jpg)   62.65    0.51
  17    MOL009091     Xanthogalenol                                         C~21~H~22~O~5~     ![](ECAM2019-7342635.tab1.i017.jpg)   41.08    0.32

###### 

Information of potential gene targets for treating fracture from *Drynariae Rhizoma*.

  No.   PDB ID   Gene target
  ----- -------- -------------
  1     1HSZ     ADH1B
  2     1HT0     ADH1C
  3     1D1T     ADH7
  4     1H0C     AGXT
  5     3CQW     AKT1
  6     1O6L     AKT2
  7     2GLQ     ALPP
  8     1ANG     ANG
  9     1HAK     ANXA5
  10    1E3G     AR
  11    2NZ2     ASS1
  12    1ONQ     B2M
  13    1XLV     BCHE
  14    1ES7     BMP2
  15    1M4U     BMP7
  16    1ES7     BMPR1A
  17    1UWJ     BRAF
  18    1A42     CA2
  19    1ICE     CASP1
  20    1K86     CASP7
  21    2C2Z     CASP8
  22    2HRB     CBR3
  23    1JBQ     CBS
  24    1ONQ     CD1A
  25    1POZ     CD44
  26    2OBD     CETP
  27    1XMI     CFTR
  28    3DRB     CKB
  29    1NN6     CMA1
  30    3BWY     COMT
  31    1NM8     CRAT
  32    1C8P     CSF2RB
  33    1BYG     CSK
  34    1CSB     CTSB
  35    1LYW     CTSD
  36    1CGH     CTSG
  37    1JKL     DAPK1
  38    2HHA     DPP4
  39    1M17     EGFR
  40    1H1B     ELANE
  41    1R5K     ESR1
  42    1QKM     ESR2
  43    2PJL     ESRRA
  44    1F0R     F10
  45    1A3B     F2
  46    1Z6J     F3
  47    1Z6J     F7
  48    1RFN     F9
  49    2FGI     FGFR1
  50    2PVY     FGFR2
  51    2BH9     G6PD
  52    1ZNQ     GAPDH
  53    1OGS     GBA
  54    1J78     GC
  55    1PUB     GM2A
  56    1J1B     GSK3B
  57    1GRE     GSR
  58    1XWK     GSTM1
  59    11GS     GSTP1
  60    2C3Q     GSTT1
  61    2VQM     HDAC4
  62    1GMN     HGF
  63    1HWL     HMGCR
  64    1S8C     HMOX1
  65    5P21     HRAS
  66    1DHT     HSD17B1
  67    1ZBQ     HSD17B4
  68    1YET     HSP90AA1
  69    2OJ9     IGF1R
  70    1ZT3     IGFBP1
  71    2ILK     IL10
  72    1G0Y     IL1R1
  73    2CYK     IL4
  74    1TYL     INS
  75    2AUH     INSR
  76    1QCY     ITGA1
  77    2B7A     JAK2
  78    1ZSX     KCNAB2
  79    1QPC     LCK
  80    1I0Z     LDHB
  81    1KJL     LGALS3
  82    1TVO     MAPK1
  83    1JNK     MAPK10
  84    1A9U     MAPK14
  85    1UKI     MAPK8
  86    2DFD     MDH2
  87    1GCZ     MIF
  88    1DMT     MME
  89    1HFC     MMP1
  90    1QIA     MMP3
  91    1JAP     MMP8
  92    1SD2     MTAP
  93    2P54     NCOA1
  94    1MVC     NCOA2
  95    2IIP     NNMT
  96    1M4U     NOG
  97    1NSI     NOS2
  98    1KBQ     NQO1
  99    1UPV     NR1H2
  100   3FXV     NR1H4
  101   1NRL     NR1I2
  102   1P93     NR3C1
  103   2A3I     NR3C2
  104   1YOW     NR5A1
  105   1WWA     NTRK1
  106   1WWB     NTRK2
  107   1OTH     OTC
  108   1WOK     PARP1
  109   2QYK     PDE4A
  110   1PTW     PDE4D
  111   1ZUC     PGR
  112   2VGB     PKLR
  113   1VJA     PLAU
  114   2PK4     PLG
  115   1NRG     PNPO
  116   1V04     PON1
  117   1B1C     POR
  118   2P54     PPARA
  119   2J14     PPARD
  120   1ZEO     PPARG
  121   1CYN     PPIB
  122   1QMV     PRDX2
  123   2GU8     PRKACA
  124   1LQV     PROCR
  125   1HDR     QDPR
  126   1QAB     RBP4
  127   2G1N     REN
  128   1MVC     RXRA
  129   1OLM     SEC14L2
  130   1F5F     SHBG
  131   1I92     SLC9A3R1
  132   2C9V     SOD1
  133   1YOL     SRC
  134   1P49     STS
  135   1J99     SULT2A1
  136   1NAV     THRA
  137   1NAX     THRB
  138   1A8M     TNF
  139   1HTI     TPI1
  140   1D0A     TRAF2
  141   1OIZ     TTPA
  142   1QAB     TTR
  143   1UOU     TYMP
  144   3CS4     VDR

###### 

Gene targets with the top 4 degree values, betweenness centrality, and closeness centrality.

  No.   Gene targets   Degree (rank)   Betweenness centrality (rank)   Closeness centrality (rank)
  ----- -------------- --------------- ------------------------------- -----------------------------
  1     NCOA1          15 (1)          0.038 (1)                       0.505 (1)
  2     MAPK1          13 (2)          0.023 (3)                       0.464 (4)
  3     GSK3B          12 (3)          0.028 (2)                       0.502 (2)
  4     TTPA           12 (4)          0.022 (4)                       0.466 (3)

###### 

Five important protein targets with top degree of *Drynariae Rhizoma*.

  No.   Degree   PDB ID   Protein target name
  ----- -------- -------- ---------------------
  1     27       1TVO     MAPK1
  2     23       1YOL     SRC
  3     22       5P21     HRAS
  4     20       1MVC     RXRA
  5     18       2P54     NCOA1

###### 

Molecular docking of three important protein targets from *Drynariae Rhizoma*.

  Protein target   PDB ID   Ingredients                                           Dock-IN score
  ---------------- -------- ----------------------------------------------------- ---------------
  NCOA1            1NQ7     (+)-Catechin                                          7.111
  RXRA             1DSZ     (+)-Catechin                                          4.624
  SRC              1O4R     (+)-Catechin                                          5.908
  NCOA1            1NQ7     (2R)-5,7-Dihydroxy-2-(4-hydroxyphenyl)chroman-4-one   6.694
  RXRA             1DSZ     (2R)-5,7-Dihydroxy-2-(4-hydroxyphenyl)chroman-4-one   4.605
  SRC              1O4R     (2R)-5,7-Dihydroxy-2-(4-hydroxyphenyl)chroman-4-one   5.783
  NCOA1            1NQ7     22-Stigmasten-3-one                                   8.422
  RXRA             1DSZ     22-Stigmasten-3-one                                   5.553
  SRC              1O4R     22-Stigmasten-3-one                                   5.425
  NCOA1            1NQ7     Aureusidin                                            7.153
  RXRA             1DSZ     Aureusidin                                            4.622
  SRC              1O4R     Aureusidin                                            5.861
  NCOA1            1NQ7     Beta-sitosterol                                       8.34
  RXRA             1DSZ     Beta-sitosterol                                       5.587
  SRC              1O4R     Beta-sitosterol                                       5.374
  NCOA1            1NQ7     Cycloartenone                                         8.427
  RXRA             1DSZ     Cycloartenone                                         5.658
  SRC              1O4R     Cycloartenone                                         5.693
  NCOA1            1NQ7     Cyclolaudenol                                         8.376
  RXRA             1DSZ     Cyclolaudenol                                         5.534
  SRC              1O4R     Cyclolaudenol                                         5.376
  NCOA1            1NQ7     Cyclolaudenol acetate                                 8.422
  RXRA             1DSZ     Cyclolaudenol acetate                                 7.052
  SRC              1O4R     Cyclolaudenol acetate                                 6.364
  NCOA1            1NQ7     Davallioside A_qt                                     7.904
  RXRA             1DSZ     Davallioside A_qt                                     5.779
  SRC              1O4R     Davallioside A_qt                                     5.58
  NCOA1            1NQ7     Digallate                                             4.313
  RXRA             1DSZ     Digallate                                             3.789
  SRC              1O4R     Digallate                                             3.671
  NCOA1            1NQ7     Eriodictyol                                           7.109
  RXRA             1DSZ     Eriodictyol                                           4.628
  SRC              1O4R     Eriodictyol                                           5.821
  NCOA1            1NQ7     Eriodictyol (flavanone)                               7.113
  RXRA             1DSZ     Eriodictyol (flavanone)                               4.633
  SRC              1O4R     Eriodictyol (flavanone)                               5.824
  NCOA1            1NQ7     Kaempferol                                            7.125
  RXRA             1DSZ     Kaempferol                                            4.613
  SRC              1O4R     Kaempferol                                            5.929
  NCOA1            1NQ7     Luteolin                                              7.089
  RXRA             1DSZ     Luteolin                                              4.621
  SRC              1O4R     Luteolin                                              5.847
  NCOA1            1NQ7     Naringenin                                            7.12
  RXRA             1DSZ     Naringenin                                            6.016
  SRC              1O4R     Naringenin                                            5.883
  NCOA1            1NQ7     Stigmasterol                                          8.376
  RXRA             1DSZ     Stigmasterol                                          5.918
  SRC              1O4R     Stigmasterol                                          5.3
  NCOA1            1NQ7     Xanthogalenol                                         5.387
  RXRA             1DSZ     Xanthogalenol                                         7.093
  SRC              1O4R     Xanthogalenol                                         7.142

###### 

The protein class corresponding to potential targets for treating fracture from main active ingredients of *Drynariae Rhizoma*.

  No.   Gene name   Protein class
  ----- ----------- ------------------------------------------------------------------------
  1     ADH1B       Oxidoreductase
  2     ADH1C       Oxidoreductase
  3     ADH7        Oxidoreductase
  4     AGXT        Transferase
  5     AKT1        Calcium-binding protein; kinase; transfer/carrier protein; transferase
  6     AKT2        Calcium-binding protein; kinase; transfer/carrier protein; transferase
  7     ALPP        Hydrolase; phosphatase
  8     ANG         None
  9     ANXA5       None
  10    AR          Nucleic acid binding; receptor; transcription factor
  11    ASS1        Ligase
  12    B2M         Defense/immunity protein
  13    BCHE        None
  14    BMP2        Signaling molecule
  15    BMP7        Signaling molecule
  16    BMPR1A      Kinase; receptor; transferase
  17    BRAF        None
  18    CA2         None
  19    CASP1       Enzyme modulator; hydrolase; protease
  20    CASP7       Enzyme modulator; hydrolase; protease
  21    CASP8       Enzyme modulator; hydrolase; protease
  22    CBR3        None
  23    CBS         Hydrolase; isomerase; lyase
  24    CD1A        None
  25    CD44        None
  26    CETP        None
  27    CFTR        Transporter
  28    CKB         Kinase; transferase
  29    CMA1        Hydrolase; protease
  30    COMT        Transferase
  31    CRAT        Transferase
  32    CSF2RB      Receptor
  33    CSK         None
  34    CTSB        Enzyme modulator; hydrolase; protease
  35    CTSD        Hydrolase; protease
  36    CTSG        Hydrolase; protease
  37    DAPK1       Kinase; transferase
  38    DPP4        Enzyme modulator; hydrolase; protease
  39    EGFR        None
  40    ELANE       Hydrolase; protease
  41    ESR1        Nucleic acid binding; receptor; transcription factor
  42    ESR2        Nucleic acid binding; receptor; transcription factor
  43    ESRRA       Nucleic acid binding; receptor; transcription factor
  44    F10         Hydrolase; protease
  45    F2          Hydrolase; protease
  46    F3          Defense/immunity protein; receptor
  47    F7          Hydrolase; protease
  48    F9          Hydrolase; protease
  49    FGFR1       None
  50    FGFR2       None
  51    G6PD        Oxidoreductase
  52    GAPDH       Oxidoreductase
  53    GBA         None
  54    GC          Transfer/carrier protein
  55    GM2A        Transfer/carrier protein
  56    GSK3B       Kinase; transferase
  57    GSR         Oxidoreductase
  58    GSTM1       None
  59    GSTP1       None
  60    GSTT1       None
  61    HDAC4       None
  62    HGF         Hydrolase; protease
  63    HMGCR       None
  64    HMOX1       Oxidoreductase
  65    HRAS        Enzyme modulator
  66    HSD17B1     Oxidoreductase
  67    HSD17B4     None
  68    HSP90AA1    Chaperone
  69    IGF1R       None
  70    IGFBP1      Enzyme modulator
  71    IL10        None
  72    IL1R1       Receptor
  73    IL4         None
  74    INS         None
  75    INSR        None
  76    ITGA1       None
  77    JAK2        None
  78    KCNAB2      Oxidoreductase; transporter
  79    LCK         None
  80    LDHB        Oxidoreductase
  81    LGALS3      Cell adhesion molecule; signaling molecule
  82    MAPK1       Kinase; transferase
  83    MAPK10      Kinase; transferase
  84    MAPK14      Kinase; transferase
  85    MAPK8       Kinase; transferase
  86    MDH2        Oxidoreductase
  87    MIF         None
  88    MME         Hydrolase; protease
  89    MMP1        Hydrolase; protease
  90    MMP3        Hydrolase; protease
  91    MMP8        Hydrolase; protease
  92    MTAP        Transferase
  93    NCOA1       Transcription factor; transferase
  94    NCOA2       Transcription factor; transferase
  95    NNMT        Transferase
  96    NOG         None
  97    NOS2        None
  98    NQO1        None
  99    NR1H2       Nucleic acid binding; receptor; transcription factor
  100   NR1H4       Nucleic acid binding; receptor; transcription factor
  101   NR1I2       Nucleic acid binding; receptor; transcription factor
  102   NR3C1       Nucleic acid binding; receptor; transcription factor
  103   NR3C2       Nucleic acid binding; receptor; transcription factor
  104   NR5A1       Transcription factor
  105   NTRK1       None
  106   NTRK2       None
  107   OTC         None
  108   PARP1       None
  109   PDE4A       None
  110   PDE4D       None
  111   PGR         Nucleic acid binding; receptor; transcription factor
  112   PKLR        None
  113   PLAU        Hydrolase; protease
  114   PLG         Hydrolase; protease
  115   PNPO        Oxidoreductase
  116   PON1        None
  117   POR         None
  118   PPARA       Nucleic acid binding; receptor; transcription factor
  119   PPARD       Nucleic acid binding; receptor; transcription factor
  120   PPARG       Nucleic acid binding; receptor; transcription factor
  121   PPIB        None
  122   PRDX2       Oxidoreductase
  123   PRKACA      None
  124   PROCR       Enzyme modulator; receptor
  125   QDPR        Oxidoreductase
  126   RBP4        Transfer/carrier protein
  127   REN         Hydrolase; protease
  128   RXRA        Nucleic acid binding; receptor; transcription factor
  129   SEC14L2     None
  130   SHBG        None
  131   SLC9A3R1    None
  132   SOD1        Oxidoreductase
  133   SRC         None
  134   STS         Hydrolase
  135   SULT2A1     None
  136   THRA        Nucleic acid binding; receptor; transcription factor
  137   THRB        Nucleic acid binding; receptor; transcription factor
  138   TNF         Signaling molecule
  139   TPI1        Isomerase
  140   TRAF2       Signaling molecule
  141   TTPA        Transfer/carrier protein
  142   TTR         Transfer/carrier protein; transporter
  143   TYMP        Transferase
  144   VDR         Nucleic acid binding; receptor; transcription factor
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